Currently, there are 4.70M common shares owned by the public and among those 4.08M shares have been available to trade.
The company’s stock has a 5-day price change of -77.36% and -97.70% over the past three months. EFTR shares are trading -97.58% year to date (YTD), with the 12-month market performance down to -98.61% lower. It has a 12-month low price of $1.14 and touched a high of $22.50 over the same period. EFTR has an average intraday trading volume of 352.11K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -80.33%, -83.97%, and -97.15% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of eFFECTOR Therapeutics Inc (NASDAQ: EFTR) shares accounts for 15.86% of the company’s 4.70M shares outstanding.
It has a market capitalization of $1.33M and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$9.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.33% over the week and 11.03% over the month.
Earnings per share for the fiscal year are expected to increase by 65.64%, and 60.00% over the next financial year.
Looking at the support for the EFTR, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on January 25, 2022, with the firm’s price target at $20-$6.20. Stifel coverage for the eFFECTOR Therapeutics Inc (EFTR) stock in a research note released on November 09, 2021 offered a Buy rating with a price target of $20. Credit Suisse was of a view on October 12, 2021 that the stock is Outperform, while Mizuho gave the stock Buy rating on October 04, 2021, issuing a price target of $20. JMP Securities on their part issued Mkt Outperform rating on September 21, 2021.
